Alpine Immune Sciences Inc (NASDAQ:ALPN) Sees Significant Decline in Short Interest

Alpine Immune Sciences Inc (NASDAQ:ALPN) was the recipient of a large drop in short interest in November. As of November 29th, there was short interest totalling 12,700 shares, a drop of 27.4% from the November 14th total of 17,500 shares. Based on an average trading volume of 24,400 shares, the short-interest ratio is presently 0.5 days. Approximately 0.2% of the shares of the stock are short sold.

NASDAQ:ALPN opened at $3.68 on Friday. The business’s 50-day moving average price is $2.97 and its two-hundred day moving average price is $3.87. Alpine Immune Sciences has a twelve month low of $2.25 and a twelve month high of $8.24. The stock has a market cap of $67.10 million, a P/E ratio of -1.40 and a beta of 1.78. The company has a quick ratio of 3.84, a current ratio of 3.84 and a debt-to-equity ratio of 0.47.

Alpine Immune Sciences (NASDAQ:ALPN) last released its quarterly earnings results on Wednesday, November 13th. The biotechnology company reported ($0.62) earnings per share for the quarter, beating the consensus estimate of ($0.68) by $0.06. The business had revenue of $0.29 million during the quarter, compared to analysts’ expectations of $0.38 million. On average, equities research analysts expect that Alpine Immune Sciences will post -2.54 EPS for the current fiscal year.

Large investors have recently added to or reduced their stakes in the business. Jacobs Levy Equity Management Inc. purchased a new stake in shares of Alpine Immune Sciences in the 2nd quarter valued at about $90,000. Renaissance Technologies LLC raised its holdings in shares of Alpine Immune Sciences by 10.8% in the 2nd quarter. Renaissance Technologies LLC now owns 106,261 shares of the biotechnology company’s stock valued at $447,000 after acquiring an additional 10,400 shares in the last quarter. Hikari Power Ltd increased its position in shares of Alpine Immune Sciences by 52.9% during the 3rd quarter. Hikari Power Ltd now owns 185,587 shares of the biotechnology company’s stock valued at $735,000 after purchasing an additional 64,224 shares during the last quarter. Finally, Vanguard Group Inc. increased its position in shares of Alpine Immune Sciences by 67.7% during the 2nd quarter. Vanguard Group Inc. now owns 202,582 shares of the biotechnology company’s stock valued at $853,000 after purchasing an additional 81,800 shares during the last quarter. 46.80% of the stock is currently owned by hedge funds and other institutional investors.

Several analysts have weighed in on the company. Zacks Investment Research cut Alpine Immune Sciences from a “buy” rating to a “hold” rating in a report on Thursday. Piper Jaffray Companies lowered their price target on Alpine Immune Sciences to $8.00 and set an “overweight” rating on the stock in a report on Wednesday, November 13th. They noted that the move was a valuation call. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Alpine Immune Sciences has a consensus rating of “Buy” and a consensus target price of $9.31.

About Alpine Immune Sciences

Alpine Immune Sciences, Inc focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202, a programmed cell death protein ligand 1 (PD-L1)/cytotoxic T-lymphocyte associated protein 4 (CTLA-4) antagonist with PD-L1 dependent CD28 costimulation for the treatment of cancer.

Featured Article: Stop Order Uses For Individual Investors

Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with's FREE daily email newsletter.


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit